In omega-3 fatty acid trials, EPA alone yields greater CV risk reduction vs. EPA plus DHA

in omega 3 fatty acid trials epa alone yields greater cv risk reduction vs epa plus dha

Sumary of In omega-3 fatty acid trials, EPA alone yields greater CV risk reduction vs. EPA plus DHA:

  • July 22, 2021 1 min read Source/Disclosures Published by: Disclosures: Khan reports no relevant financial disclosures.
  • Back to Healio In a meta-analysis of omega-3 fatty acid trials, eicosapentaenoic acid monotherapy yielded the greatest reduction in CV risk vs.
  • Bhatt “In this systematic review and meta-analysis, we noted moderate certainty of evidence favoring omega-3 fatty acids for reducing CV mortality and outcomes,” Cardiology Today Intervention Section Editor Deepak L.
  • ” Source: Adobe Stock Bhatt and colleagues analyzed the effectiveness of omega-3 fatty acids on CV outcomes while examining the variability in EPA compared with a combination of EPA and DHA.
  • The researchers evaluated CV mortality, nonfatal CV outcomes, bleeding and atrial fibrillation in a meta-analysis of 38 randomized clinical trials of omega-3 fatty acids, categorized by EPA monotherapy or EPA/DHA therapy.
  • The clinical trials analyzed were published before June 7, 2021. In 149,051 individuals who participated in the 38 trials, omega-3 fatty acid use correlated with reduced risk for CV mortality (RR = 0.93;
  • “This meta-analysis provides reassurance about the role of omega-3 fatty acids, specifically prescription EPA,” Bhatt said in a press release.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.